Pakistan to receive 17.2m doses as Covax sets out vaccination plans in first distribution list

Published February 3, 2021
Medical attendants prepare to vaccinate health workers with Chinese-made Sinopharm Covid-19 vaccine at a vaccination centre in Karachi on February 3. — AFP
Medical attendants prepare to vaccinate health workers with Chinese-made Sinopharm Covid-19 vaccine at a vaccination centre in Karachi on February 3. — AFP

The Covax programme for Covid-19 vaccines published its first distribution list on Wednesday, planning enough doses for dozens of countries to immunise more than three per cent of their populations by mid-year.

The list comes with concerns over whether lower-income countries will be left out of the immunisation race dominated by rich nations, a problem Covax was set up to resolve.

It broke down for the first time how the programme's initial 337.2 million doses will be distributed, with first deliveries expected in late February.

Some 145 countries are set to receive enough doses to immunise 3.3pc of their population by mid-2021.

A statement said the initial distribution was in line with a target “to protect the most vulnerable groups such as health care workers” in the first half of the year.

Countries will receive doses in proportion to population size, with the most going to India (97.2m), Pakistan (17.2m), Nigeria (16m), Indonesia (13.7m), Bangladesh (12.8m) and Brazil (10.6m).

“This is fantastic. We can start vaccinating. It is coming in the next weeks,” Ann Lindstrand, coordinator for a World Health Organisation immunisation programme, told a press conference.

Covax is co-led by the WHO, the Gavi vaccine alliance, and the Coalition for Epidemic Preparedness Innovations (CEPI).

Funding is covered through donations for the 92 lower- and lower-middle income economies involved, while for richer countries, buying in operates as a back-up insurance policy for their own vaccination programmes.

The distribution list includes 240m doses of the AstraZeneca-Oxford vaccine, licensed to the Serum Institute of India (SII); 96m doses of AstraZeneca-Oxford vaccine; and 1.2m doses of the Pfizer-BioNTech vaccine.

The Pfizer-BioNTech vaccine is the only one so far to have received emergency use approval from the WHO. Evaluation is underway for the AstraZeneca-Oxford vaccine.

Both require two injected doses.

Wealthy self-financing countries were on the list in addition to lower-income nations, including South Korea (2.6m doses), Canada (1.9m) and New Zealand (250,000).

The list is non-binding and may change, the statement stressed, but would allow countries to plan for how many doses they will receive in the first rounds.

Longer term, Covax aims to secure enough vaccines for at least the most vulnerable 20pc in participating countries by the end of 2021.

Opinion

Editorial

Digital growth
Updated 25 Apr, 2024

Digital growth

Democratising digital development will catalyse a rapid, if not immediate, improvement in human development indicators for the underserved segments of the Pakistani citizenry.
Nikah rights
25 Apr, 2024

Nikah rights

THE Supreme Court recently delivered a judgement championing the rights of women within a marriage. The ruling...
Campus crackdowns
25 Apr, 2024

Campus crackdowns

WHILE most Western governments have either been gladly facilitating Israel’s genocidal war in Gaza, or meekly...
Ties with Tehran
Updated 24 Apr, 2024

Ties with Tehran

Tomorrow, if ties between Washington and Beijing nosedive, and the US asks Pakistan to reconsider CPEC, will we comply?
Working together
24 Apr, 2024

Working together

PAKISTAN’S democracy seems adrift, and no one understands this better than our politicians. The system has gone...
Farmers’ anxiety
24 Apr, 2024

Farmers’ anxiety

WHEAT prices in Punjab have plummeted far below the minimum support price owing to a bumper harvest, reckless...